GH

Guardant Health, Inc.

Next est. report 2026-07-30 · AMC

AI '25: Data Owners AI '25: Healthcare ApplicationsData Owners '25: Healthcare, Claims & Clinical DataGenomics '25: Molecular Diagnostics & Clinical GenomicsInfra Built in ZIRP '25: HC PlatformsMedTech Long '25: Cancer Diagnostics, Platforms & CareMedTech Long '25: Centralized Lab Diagnostics MedTech Long '26: Diagnostics & Early Detection

Loading…

Overview

Guardant Health, Inc. develops blood tests and data solutions for cancer care. Its oncology tests, like Guardant360 and Reveal, guide treatment and monitor adva

Guardant Health, Inc. develops blood tests and data solutions for cancer care. Its oncology tests, like Guardant360 and Reveal, guide treatment and monitor advanced and early-stage cancers. The Shield test offers early colorectal and multi-cancer detection. In Q1 2026, oncology was ~68% of revenue, biopharma ~18%, and screening ~14%, serving physicians, patients, and pharmaceutical firms.

What They Do (Plain English & Analogies): Guardant Health is a company that helps doctors fight cancer using advanced blood tests, often called "liquid biopsies." Instead of needing a piece of tissue from a tumor, they can find tiny fragments of cancer DNA in a patient's blood. This allows doctors to choose the best treatments, monitor if those treatments are working, and even screen for cancer early, like for colorectal cancer. Think of it like a highly sensitive "bloodhound" for cancer, sniffing out even the smallest traces of the disease to guide patient care. They also partner with drug companies to help develop new cancer medicines and provide valuable data insights.
Very Brief History: Guardant Health, Inc. was founded in 2011 by Helmy Eltoukhy and AmirAli Talasaz. The company quickly became a leader in precision oncology with the launch of products like Guardant360 for advanced cancer. Key milestones include receiving FDA approval for Guardant360 CDx in 2020, Medicare coverage for Guardant Reveal for colorectal cancer (CRC) surveillance in early 2025, and the FDA approval of its Shield blood test for CRC screening in 2024. In December 2025, Guardant Health acquired MetaSight Diagnostics to expand into multi-disease detection.
"Street Stereotype": Guardant Health is generally perceived as a leading innovator in precision oncology, particularly in the liquid biopsy space. Investors and analysts view them as a company that has successfully built out a strong technological platform and data network, leveraging infrastructure developed during the ZIRP era. They are seen as a key player in the shift towards personalized medicine and early cancer detection, with significant growth potential in centralized lab diagnostics, especially with their Shield colorectal cancer screening test. They are also recognized for their integration of AI into their data-rich workflows.
Subsidiaries On Linked In*: {"subsidiaries":[]}
Customer Sectors & Example Clients: Guardant Health's customers are primarily in the healthcare sector, including oncologists, primary care physicians, and health systems. They also serve biopharmaceutical companies and medical institutions. Specific example clients mentioned include Merck (for companion diagnostics and novel therapies), Quest Diagnostics (for national sales and connectivity system integration for Shield), Arvinas and Pfizer (for CDx approvals), Daiichi Sankyo (for ENHERTU approval), Nuvalent (for companion diagnostics), and Manulife (for Shield Multi-Cancer Detection in Asia).
New Customers / Segments They'Re Targeting: Guardant Health is actively targeting several new customer segments and markets. For its Shield colorectal cancer screening test, they are expanding into the under-65 commercial population, which is expected to broaden their reach beyond Medicare beneficiaries. They are also expanding the Shield Multi-Cancer Detection (MCD) report to patients who opt-in, covering 9 additional cancer types, aiming to build the largest clinical database of MCD outcomes from U.S. patients. Geographically, they have launched Shield MCD in Asia through a partnership with Manulife, initially in Hong Kong, the Philippines, and Singapore. Furthermore, with the expansion of Guardant360 Tissue to whole transcriptome, they aim to convert current non-users of their tissue-based comprehensive genomic profiling.
Supply Chain And Sourcing Geographies: Guardant Health manages its supply chain operations, including procurement, planning, inventory, and supplier relationships. The company's Senior Vice President of Operations oversees clinical sample production, manufacturing, facilities, and supply chain for its in vitro diagnostic (IVD) products. While specific sourcing geographies are not explicitly detailed, the company emphasizes responsible supply chain operations and works with over 3,000 active suppliers. The focus is on optimizing logistics, reducing costs, and ensuring timely material and service availability for its biotech and turnkey environment.
Sales Geographies And Expansion Plans: Guardant Health currently sells its products within the United States and internationally. Their CDx franchise spans 26 approvals across the U.S., Japan, and Europe. They have a direct service provision in Italy based on Guardant360 CDx technology. For their Shield Multi-Cancer Detection (MCD) test, they have expanded into Asia through a partnership with Manulife, launching in Hong Kong, the Philippines, and Singapore. The company is committed to expanding access to its innovative blood-based tests across Europe, partnering with hospitals and strategic distributors. They also have offices in Japan, China, and India, indicating a broader presence in Asia.
How Key Themes May Help/Hurt: Guardant Health is strongly positioned to benefit from the 'AI '25: Data Owners' theme. The company's extensive 'data treasury' from over 1 million patient samples and 500,000 epigenetic profiles across more than 100 tumor types provides a significant proprietary dataset. Their InfinityAI learning engine directly leverages this data to uncover novel biological signatures, power new 'Smart App' development, and accelerate therapeutic discovery for biopharma partners, aligning with the theme's bull case of specialized datasets creating defensible competitive advantages and driving tangible ROI through AI. The Shield Multi-Cancer Detection report, with patient opt-in, is building what is expected to be the largest clinical database of MCD outcomes from U.S. patients, further solidifying their data moat. This data-driven approach enhances product innovation and supports their technological edge, leading to margin improvement and revenue growth. However, potential bear points for the theme, such as the increasing complexity of global AI and data privacy regulations, could necessitate increased investment in legal and technical compliance, potentially impacting operational costs.

3 Main Long-Term Bull Details

Comprehensive Smart Platform and AI-Driven Innovation: Guardant Health's Smart platform, powered by InfinityAI and a vast data treasury of over 1 million patient samples, drives continuous innovation, new clinical applications, and therapeutic discovery, creating a compounding flywheel effect for deeper adoption and a strong competitive moat.
Rapidly Scaling Screening Business with Strong Reimbursement: The Shield colorectal cancer screening test is a significant multiyear growth driver, having achieved ADLT status with a $1,495 Medicare reimbursement rate secured through 2027 and demonstrating a high adherence rate of over 90%. Strategic collaborations with Quest Diagnostics and Manulife are set to broaden its national and international reach and drive substantial volume growth.
Clear Path to Profitability for Core Business: The core oncology and biopharma business is expected to be free cash flow positive for the full year 2026, with a commitment to achieving company-wide cash flow breakeven by the end of 2027. Operational efficiencies, such as the NovaSeq X transition for Guardant360 Liquid, are improving gross margins and supporting disciplined financial management.

3 Main Long-Term Bear Details

Significant Cash Burn in Screening Business: The Shield screening business continues to incur substantial cash burn, projected at around $185 million to $195 million for the full year 2026, which delays overall company-wide free cash flow positivity and introduces execution risk in scaling the sales force and integrating new partnerships effectively.
Potential for Shield ASP Decline and Reimbursement Challenges: While Shield's ADLT rate is stable, its average selling price (ASP) is expected to tick down for the remainder of 2026 due to a changing mix with increasing demand from the under-65 commercial population, where reimbursement rates may be lower or less consistent than Medicare.
Intensifying Competition and Regulatory Hurdles: The liquid biopsy and cancer screening markets are highly competitive, with established players and new entrants vying for market share. Guardant Health faces ongoing regulatory and evidence generation challenges for new indications and products, and any adverse reimbursement decisions or delays in FDA approvals could significantly impact revenue and growth.

Competitors And Differentiation: Guardant Health operates in a competitive landscape with companies like SOPHiA GENETICS, Caris Life Sciences, Castle Biosciences, Biodesix, Tempus AI, Exact Sciences, Natera, Illumina/GRAIL, and NeoGenomics. Guardant differentiates itself through its comprehensive 'one platform for the entire patient journey' approach, spanning profiling, monitoring, and screening. Their proprietary Smart platform, powered by InfinityAI, leverages a vast data treasury (over 1 million patient samples and 500,000 epigenetic profiles) to develop highly sensitive and accurate tests, uncover novel biological signatures, and accelerate therapeutic discovery. They are a leader in tissue-free MRD testing. For colorectal cancer screening, Shield's over 90% adherence rate is a key differentiator compared to other noninvasive modalities. They also emphasize their strong brand in oncology, which helps drive adoption of new products.
Recent Performance & What The Market'S Focused On: Guardant Health delivered a strong start to 2026, with Q1 revenue reaching $302 million, representing 48% year-over-year growth, surpassing the $1 billion trailing 12-month revenue milestone. This growth was broad-based across Oncology (36% Y/Y), Biopharma & Data (17% Y/Y), and Screening (significant increase from $6 million to $42 million Y/Y). The company raised its full-year 2026 revenue guidance to $1.30 billion to $1.32 billion. The market is focused on the continued acceleration of Shield volumes, particularly with the impact of the Quest Diagnostics collaboration and direct-to-consumer campaigns, as well as the progress of Reveal's reimbursement submissions to MolDx for new indications. Investors are also closely watching the trajectory towards company-wide cash flow breakeven by the end of 2027, balancing the heavy investments in Shield with improving profitability in the core business.

Revenue Segments And Estimated Mix: Oncology — Mix: ~67.9%; Source: Q1 2026 transcript; Trend: Grew 36% year-over-year to $205 million in Q1 2026, slightly down as a percentage of total revenue compared to FY2025.
Biopharma & Data — Mix: ~17.5%; Source: Q1 2026 transcript; Trend: Grew 17% year-over-year to $53 million in Q1 2026, slightly down as a percentage of total revenue compared to FY2025.
Screening — Mix: ~13.9%; Source: Q1 2026 transcript; Trend: Grew significantly year-over-year to $42 million in Q1 2026 from $6 million in Q1 2025, representing a substantial increase as a percentage of total revenue.
Product Brands: Guardant360 Liquid
Guardant360 Tissue
Guardant360 CDx
GuardantOMNI
GuardantINFORM
Guardant Reveal
Reveal Ultra
Shield
Shield Multi-Cancer Detection (MCD) Report
GuardantConnect
Guardant-19
InfinityAI
Smart platform

Bull / Bear Details

Guardant Health's bullish investment case is strengthened by its remarkable Q1 2026 performance, significantly raised full-year guidance, and accelerating comme

Thesis

Guardant Health's bullish investment case is strengthened by its remarkable Q1 2026 performance, significantly raised full-year guidance, and accelerating commercial flywheel. The company leverages its advanced oncology Smart Platform, AI-driven data insights, and rapidly scaling Shield screening business, which continues to break records. A clear path to profitability for its core business and company-wide cash flow breakeven by late 2027 underpins sustained growth and market leadership in precision oncology and early cancer detection as of 2026-07-17.

Bull case

Guardant's oncology business is demonstrating exceptional and accelerating growth, with Q1 2026 revenue up 36% year-over-year and volume up 47%. Guardant360 Liquid volumes grew 30%, while Reveal remained the fastest-growing product with over 100% year-over-year volume growth, driven by strong adoption in MRD and therapy response monitoring.
The Shield colorectal cancer screening test is a significant multiyear growth driver, delivering $42 million in Q1 2026 revenue from approximately 44,000 tests, a substantial increase from the prior year. Strong momentum in March, fueled by DTC campaigns, influencer partnerships, and the nationwide Quest collaboration, led to a raised 2026 screening revenue guidance of $186 million to $198 million.
Guardant Health is demonstrating a clear path to profitability and strong financial management. The core business (excluding screening) is expected to be free cash flow positive for the full year 2026, with a commitment to company-wide cash flow breakeven by the end of 2027. Operational efficiencies, including the NovaSeq X transition for Guardant360 Liquid, are improving gross margins.

Bear case

Despite strong volume growth, the Shield screening business continues to incur significant cash burn, with Q1 2026 free cash flow burn at $71 million. While the full-year burn is expected to improve, heavy investment in commercial expansion and marketing for Shield delays overall company-wide free cash flow positivity and introduces execution risk in scaling operations.
While Shield's ADLT rate is stable at $1,495, its average selling price (ASP) is expected to decline for the remainder of 2026 due to a changing mix, with increasing demand from the under-65 commercial population. This mix shift could impact overall revenue per test and gross profit if commercial reimbursement rates are lower or less consistent than Medicare.
The company's guidance for 2026 does not include potential upside from Quest co-promotion activities or ACS guideline inclusion for Shield, indicating these are not guaranteed or fully realized catalysts. Furthermore, the broader multi-cancer early detection (MCED) field faces evolving regulatory and evidence generation challenges, as highlighted by the Camizestrant AdCom vote.

Bull / Bear Case

Bear Case: Despite strong volume growth, the Shield screening business continues to incur significant cash burn, with Q1 2026 free cash flow burn at $71 million and a full-year 2026 projection of $185 million to $195 million. This heavy investment in commercial expansion and marketing for Shield delays overall company-wide free cash flow positivity until late 2027 and introduces execution risk. While Shield's ADLT rate is stable at $1,495, its average selling price (ASP) is expected to decline for the remainder of 2026 due to a changing mix, with increasing demand from the under-65 commercial population, where reimbursement rates may be lower or less consistent than Medicare. The company's guidance for 2026 does not fully account for potential upside from Quest co-promotion or ACS guideline inclusion, indicating these are not guaranteed or fully realized catalysts. The liquid biopsy and cancer screening markets are highly competitive, with strong players like Freenome (partnered with Abbott) emerging with competitive CRC screening tests, potentially intensifying market share battles. The stock currently trades at a high P/S ratio of ~19.2x-19.7x, significantly above the healthcare industry average, and is considered overvalued by some metrics, suggesting that future growth is already priced in. Recent insider selling also raises a yellow flag.
Bull Case: Guardant Health is demonstrating exceptional and accelerating growth across its oncology portfolio, with Q1 2026 revenue up 36% year-over-year and volume up 47%. Reveal, the fastest-growing product, saw over 100% volume growth, driven by strong adoption in MRD and therapy response monitoring. The Shield colorectal cancer screening test is a significant multiyear growth driver, delivering $42 million in Q1 2026 revenue from approximately 44,000 tests, a substantial increase from the prior year. Strong momentum from DTC campaigns, influencer partnerships, and the nationwide Quest collaboration led to a raised 2026 screening revenue guidance of $186 million to $198 million. The company is demonstrating a clear path to profitability for its core business (excluding screening), expected to be free cash flow positive for the full year 2026, with a commitment to company-wide cash flow breakeven by the end of 2027. Operational efficiencies, such as the NovaSeq X transition for Guardant360 Liquid, are improving gross margins. Recent positive developments include ACS guideline inclusion for Shield and UnitedHealth Group coverage. The liquid biopsy market itself is projected for substantial growth, with Guardant Health holding a leading position.
More Compelling & Why: Given the current valuation, the Bear Case is more compelling. The stock trades at a P/S ratio of approximately 19.2x-19.7x, which is significantly higher than the healthcare industry average of ~1.5x and suggests substantial future growth is already priced in. The strongest argument for the bear case is the continued significant cash burn from the Shield business, which delays overall company-wide free cash flow positivity until late 2027 and introduces execution risk in a rapidly competitive market. My view would flip to bullish if Guardant Health demonstrates a clear and accelerated path to company-wide free cash flow positivity, significantly reducing its cash burn while maintaining robust revenue growth, and if the competitive landscape for Shield stabilizes with clear market leadership.

Key Factors5 rows

Key Factor	Why It Matters	What To Watch	What It Signals	Where/How To Track	Free Alt Data	Paid Alt Data
Shield Test Volume Growth driven by Quest Diagnostics collaboration and Direct-to-Consumer (DTC)/Healthcare Provider (HCP) marketing campaigns.	Sustained high volume growth for Shield is critical for Guardant Health's long-term revenue targets and path to company-wide profitability, leveraging strategic partnerships and marketing investments.	Sequential Shield test volumes reported quarterly. Specific commentary on Quest's incremental contribution and the continued impact of DTC/HCP campaigns. Full-year 2026 Shield volume guidance (230,000 to 245,000 tests).	Bullish if sequential Shield test volume growth consistently exceeds the implied ~10,000 Q-over-Q average for 2026, or if Quest's contribution is explicitly quantified as significant. Bearish if sequential growth slows materially below this average.	Guardant Health quarterly earnings reports and conference calls (next expected Q2 2026 earnings in August 2026).	Google Trends: 'Guardant Shield test,' 'colorectal cancer screening blood test.' News articles on Quest Diagnostics partnership.	YipitData: Shield test order volume trends. Thinknum: Guardant Health sales and marketing job postings growth.
Confirmation of Guardant360 Liquid test transition to NovaSeq X sequencing platform.	This transition is a key operational efficiency initiative, directly reducing sequencing costs per test and improving Guardant360 Liquid's gross margins, contributing to overall profitability.	Management confirmation in the upcoming Q2 2026 earnings report that the NovaSeq X transition for Guardant360 Liquid was completed in May 2026. Monitor Guardant360 gross margin in Q2 and subsequent earnings reports.	Bullish if the transition is confirmed as completed in May 2026 and the expected cost reduction of nearly $200 per test (vs. Q1 2025) is realized, leading to improved gross margins.	Guardant Health Q2 2026 earnings report and conference call (expected August 2026).
MolDx coverage decisions for Reveal in breast cancer surveillance, immuno-oncology monitoring, and chemotherapy monitoring.	Positive reimbursement decisions from MolDx would significantly increase Reveal's average selling price (ASP) and expand its addressable market, accelerating revenue growth for this fastest-growing oncology product.	Official announcements from Guardant Health or MolDx regarding coverage decisions for submitted data packages. Management commentary on ASP upside for Reveal.	Bullish if MolDx grants positive coverage for any of the submitted indications (breast cancer surveillance, immuno-oncology monitoring, chemotherapy monitoring).	Guardant Health press releases, SEC filings (10-Q, 8-K), and quarterly earnings calls. MolDx website for coverage updates.	Industry news outlets covering MolDx decisions for liquid biopsies.	Definitive Healthcare: Medicare Part B claims data for Reveal (once covered).
FDA approval of Guardant360 Liquid as the most comprehensive liquid biopsy for therapy selection.	FDA approval would simplify ordering, enhance market perception, and act as a significant volume catalyst for Guardant360 Liquid, reinforcing its leadership in therapy selection.	Official announcement from Guardant Health regarding FDA approval for Guardant360 Liquid.	Bullish if FDA approval is received in 2026 as anticipated, potentially leading to upside beyond current oncology guidance.	Guardant Health press releases, SEC filings (8-K), and quarterly earnings calls. FDA website for device approvals.	Industry news and medical journals for FDA approval announcements.
American Cancer Society (ACS) updated colorectal cancer screening guidelines explicitly including blood-based tests like Shield.	Inclusion in ACS guidelines would significantly increase payer acceptance, broaden clinical adoption among healthcare providers, and expand the addressable market for Shield.	Official announcement from the American Cancer Society regarding updated colorectal cancer screening guidelines.	Bullish if ACS guidelines are updated to include Shield as a recommended screening option, leading to increased payer acceptance and broader clinical adoption.	American Cancer Society official website, Guardant Health press releases, and quarterly earnings calls.	News alerts from major medical organizations (e.g., American Cancer Society, JAMA, NEJM).	Milliman: Payer surveys on coverage for new screening modalities.

Key Reported Metrics, Reratings Triggers & Results3 rows

As the largest revenue segment, sustained strong growth in oncology revenue, driven by Guardant360 and Reveal, is fundamental to Guardant Health's overall finan

Key reported metrics			Rerating thresholds
Metric	Last period	Why it matters	What's needed for rerating	Rerating context	Earnings date
Oncology Revenue	36%	As the largest revenue segment, sustained strong growth in oncology revenue, driven by Guardant360 and Reveal, is fundamental to Guardant Health's overall financial performance and its stated path to company-wide cash flow breakeven by the end of 2027.	For Guardant Health's stock to rerate higher, Q2 2026 Oncology Revenue growth needs to exceed 30% year-over-year, ideally closer to or above the Q1 2026 rate of 36%. Additionally, a further upward revision to the full-year 2026 oncology revenue growth guidance (currently 28-29%) would signal continued outperformance.	Sustained and accelerating oncology revenue growth, especially above raised guidance, validates Guardant Health's precision oncology leadership and Smart Platform adoption. This signals stronger competitive positioning, potential for earlier profitability, and justifies a higher valuation multiple for its core business, supporting the path to company-wide cash flow breakeven by late 2027.	2026-07-30
Reveal Volume Growth	>100%	Reveal is Guardant Health's fastest-growing oncology product, reflecting strong adoption in MRD and therapy response monitoring. Continued high volume growth, coupled with potential ASP upside from MolDx reimbursement decisions, is critical for expanding its market leadership and contributing to oncology segment growth.	For Guardant Health's stock to rerate higher, Reveal Volume Growth needs to demonstrate sustained triple-digit year-over-year growth, ideally accelerating beyond the Q1 2026 rate of >100%. This acceleration should be accompanied by positive MolDx coverage decisions for new indications, such as breast cancer surveillance or immuno-oncology/chemotherapy monitoring.	Sustained and accelerated Reveal volume growth, particularly with expanded reimbursement, validates Guardant Health's leadership in minimal residual disease (MRD) testing and its 'Smart Platform' strategy. This drives overall oncology revenue, improves the company's path to profitability, and strengthens its competitive position in the high-growth precision oncology market, justifying a higher valuation.	2026-07-30
Screening Revenue	600%	Shield's explosive growth is a key driver for Guardant Health's future, with significant investments in commercial expansion and strategic partnerships. Continued strong performance and momentum are crucial for achieving overall revenue targets and demonstrating the success of its early detection strategy.	For Guardant Health's stock to rerate higher, Q2 2026 Screening Revenue should substantially exceed Q1's $41.6 million, ideally reaching at least $55 million. More importantly, the company needs to signal a strong likelihood of exceeding the upper end of its recently raised full-year 2026 screening revenue guidance of $198 million, potentially indicating a new trajectory towards or above $200 million.	Achieving this threshold signals Guardant Health's Shield test is gaining market traction faster than anticipated, validating its commercial strategy and recent wins. This accelerates the screening business's path to profitability, enhancing competitive position and justifying a higher valuation multiple.	2026-07-30

Key Questions

Can Guardant Health sustain the accelerated Shield volume growth seen in Q1 2026, particularly with the continued impact of the Quest collaboration and DTC camp

Can Guardant Health sustain the accelerated Shield volume growth seen in Q1 2026, particularly with the continued impact of the Quest collaboration and DTC campaigns, and how will the anticipated mix shift to under-65 commercial patients affect Shield's average selling price (ASP) and overall revenue trajectory?

Question 2: Will Guardant Health secure positive MolDx reimbursement decisions for Reveal in new indications (breast cancer surveillance, immuno-oncology, and chemotherapy monitoring) in the near term, and will the anticipated FDA approval of Guardant360 Liquid and the completion of the NovaSeq X transition further accelerate oncology volume growth and improve gross margins?
Question 3: Can Guardant Health effectively manage its significant investments in the rapidly scaling Shield screening business while demonstrating a clear trajectory towards its improved full-year 2026 free cash flow burn target and maintaining its commitment to company-wide cash flow breakeven by the end of 2027?

Earnings Transcript Summary2 rows

2026-05-07 · 2026Q1 Earnings Call

3 Things Management Is Most Focused On	Call Takeaway & Tone	Prior Quarter'S Y/Y Growth By Segment	3 Things Analysts Most Pressed On (And Mgmt Responses)	Revenue Segments
1. Accelerating growth across the oncology portfolio, particularly Guardant360 and Reveal: Management highlighted Guardant360's 36% year-over-year revenue growth and 47% volume growth, driven by Smart platform innovation and InfinityAI. Reveal was the fastest-growing product with over 100% volume growth, reflecting strong adoption in MRD and therapy response monitoring. [cite: Helmy Eltoukhy] 2. Scaling the Shield screening business and expanding market reach: Management emphasized the "phenomenal start" for Shield with $42 million revenue and 44,000 tests, fueled by improved sales rep productivity, DTC and influencer campaigns (e.g., Patrick Dempsey), and the nationwide Quest collaboration. They also noted the launch of Shield Multi-Cancer Detection in Asia. [cite: AmirAli Talasaz] 3. Achieving key reimbursement and regulatory milestones to drive future growth and ASP upside: Management is focused on MolDx submissions for Reveal (breast cancer surveillance, immuno-oncology monitoring, chemotherapy monitoring) and FDA approval for Guardant360 Liquid, which is expected to be a significant volume catalyst and simplify ordering. [cite: Helmy Eltoukhy, Michael Bell]	The overall takeaway from the call is that Guardant Health delivered a "remarkable" Q1 2026, exceeding expectations with strong and broad-based revenue growth across all segments, particularly driven by the accelerating momentum in its oncology portfolio (Guardant360 and Reveal) and the rapidly scaling Shield screening business. Management raised its full-year 2026 revenue guidance, reflecting increased confidence in its commercial execution, strategic partnerships (Quest, Manulife), and product pipeline. The tone of the call was highly positive and confident, emphasizing the validation of their strategic vision, the "new level of velocity" in their commercial flywheel, and a clear path towards profitability for the core business and company-wide cash flow breakeven by the end of 2027. [cite: Helmy Eltoukhy, Michael Bell]	Total Revenue (Q4 2025): 39% year-over-year. [cite: Michael Bell, 10] Oncology Revenue (Q4 2025): 30% year-over-year. [cite: Michael Bell, 10] Biopharma & Data Revenue (Q4 2025): 9% year-over-year. [cite: Michael Bell, 10] Screening Revenue (Q4 2025): 756.1% year-over-year (from $4.1 million in Q4 2024 to $35.1 million in Q4 2025). [cite: Michael Bell, 10]	1. Shield's accelerated volume momentum and the impact of the Quest collaboration: Analysts questioned the sustainability of the accelerated momentum seen in March and the specific contribution of Quest. Management responded that the strong March momentum, driven by DTC campaigns, influencer campaigns, and Quest going live, gives them confidence in the new guidance. They are still capturing data on Quest's incremental help but are counting on some positive contribution in their thoughtful guidance. [cite: Mark Massaro, AmirAli Talasaz] 2. Drivers of Guardant360's continued strong growth (30% Y/Y volume) despite being on the market for a decade: Analysts asked for more color on what is driving this "outsized growth." Management attributed it to the fundamental step change in capabilities offered by the Smart liquid biopsy platform, allowing for phenotype insights and new applications. They noted broad-based growth, share gains, and expanding breadth and depth of physician adoption, emphasizing that they are still in the early innings of the platform's capabilities. [cite: Subhalaxmi Nambi, Helmy Eltoukhy] 3. Reveal's over 100% growth, key market drivers, and upcoming reimbursement catalysts from MolDx submissions: Analysts inquired about the factors behind Reveal's rapid growth and the timeline/catalyst set for MolDx coverage. Management explained that growth is strong across CRC, breast, and lung cancers in the surveillance setting, with therapy monitoring also being a significant addition. They stated that progress is being made with MolDx submissions for breast cancer surveillance, immuno-oncology monitoring, and chemotherapy monitoring, and favorable outcomes would provide "ASP upside" for the MRD business. [cite: Patrick Donnelly, Helmy Eltoukhy, Michael Bell]	Total Revenue: $302 million, up 48% year-over-year. [cite: Helmy Eltoukhy] Oncology Revenue: $205 million, up 36% year-over-year. [cite: Helmy Eltoukhy] Biopharma & Data Revenue: $53 million, up 17% year-over-year. [cite: Helmy Eltoukhy] Screening Revenue: $42 million, up 600% year-over-year (from $6 million in Q1 2025). [cite: AmirAli Talasaz]

2026-02-19 · 2025Q4 Earnings Call

3 Things Management Is Most Focused On	Call Takeaway & Tone	Prior Quarter'S Y/Y Growth By Segment	3 Things Analysts Most Pressed On (And Mgmt Responses)	Revenue Segments
1. Driving adoption and expanding capabilities in oncology: Management highlighted exceptional growth in their oncology business due to new capabilities and insights from Smart Platform applications, including Guardant360 Liquid, Guardant360 tissue upgrades, and Medicare coverage for Reveal in CRC surveillance. They are also excited about Reveal for therapy monitoring and its synergistic potential with Guardant360. [cite: Helmy Eltoukhy] 2. Scaling the Shield screening business: Management emphasized Shield's extraordinary growth since launch, driven by strong demand, the expansion of their commercial organization, and strategic partnerships with Quest Diagnostics and PathGroup. They also noted the securing of ADLT pricing. [cite: AmirAli Talasaz, Michael Bell] 3. Strengthening path to profitability and improving cash flow: Management reported improved non-GAAP gross margin and reduced free cash flow burn. They expect the core business (excluding screening) to be free cash flow positive for the full year 2026 and are committed to achieving company-wide cash flow breakeven by the end of 2027. [cite: Michael Bell]	The overall takeaway from the call is that Guardant Health delivered strong financial results in Q4 and full-year 2025, driven by robust performance in its oncology business and the rapid scaling of its Shield screening product. Management provided an optimistic outlook for 2026, projecting continued strong revenue growth and emphasizing strategic investments in key growth drivers, particularly in screening. They also highlighted a clear path to profitability for the core business and a commitment to company-wide cash flow breakeven by the end of 2027. The tone of the call was positive and confident, underscoring strong execution, successful product launches, and impactful strategic partnerships, while also acknowledging the necessary ongoing investments in the screening segment.	In Q3 2025, total revenue increased 39% Y/Y. Oncology revenue grew 31% Y/Y. Biopharma and data revenue increased 18% Y/Y. Screening revenue grew 2310% Y/Y (from $1.0 million in Q3 2024 to $24.1 million in Q3 2025).	1. Reveal therapeutic monitoring opportunity: Analysts asked about the opportunity for Reveal therapeutic monitoring for both Reveal and Guardant360 volumes. Management responded that it's a significant opportunity to work synergistically with Guardant360, bridging to subsequent Guardant360 tests as patients progress, and that reimbursement wins for IO and chemo monitoring could be important growth drivers. [cite: Daniel Leonard, Helmy Eltoukhy] 2. Shield specific burn and sales rep hiring pace: Analysts inquired about the expected free cash flow burn for Shield and the pace of sales rep hiring. Management stated that Shield's burn for 2026 is expected to be similar to 2025 (around $220 million) due to continued heavy investments in commercial infrastructure. They plan to continue building out the commercial organization by reinvesting incremental gross profit into sales and marketing. [cite: Douglas Schenkel, Michael Bell, AmirAli Talasaz] 3. Shield ASP decline and international contribution: Analysts questioned the guided decline in Shield's average selling price (ASP) and the expected international contribution. Management explained that the ASP decline is primarily due to a mix impact from increasing demand from the under-65 population (non-Medicare), despite the ADLT rate being maintained for Medicare. They anticipate international contribution to Shield to be relatively small in 2026, with the majority of growth coming from the U.S. [cite: Tycho Peterson, Michael Bell]	Total revenue increased 39% year-over-year (Y/Y) to $281 million. Oncology revenue grew 30% Y/Y to $190 million. Biopharma and data revenue was up 9% Y/Y to $54.0 million. Screening revenue totaled $35.1 million from approximately 38,000 Shield tests; a specific Y/Y revenue growth percentage was not provided in the transcript, but it represents a significant increase compared to 6,400 tests in the prior year period. [cite: Michael Bell, 10]

Transcript Tidbits2 rows

2026-05-07

About Expanding Eligible Market	About Competition	About The Broader Industry	Where Things Are Headed	Updates On Theme	Broader Themes Emerging	Bullish-Leaning Quotes (Short)	Bearish-Leaning Quotes (Short)	Hiring
Guardant Health's Guardant360 Liquid, upon FDA approval, is set to become the most comprehensive FDA-approved liquid biopsy for therapy selection on the market. The company also announced a second major platform upgrade for Guardant360 Tissue, expanding RNA testing to whole transcriptome, which is expected to be a meaningful volume catalyst by converting current nonusers. Reveal is seeing strong adoption in MRD across indications and enthusiasm for its new therapy response monitoring use case. Data packages have been submitted to MolDx to support coverage for Reveal in breast cancer surveillance, immuno-oncology monitoring, and chemotherapy monitoring, with ongoing studies across more than 5 additional tumor types. The CDx franchise now spans 26 approvals across the U.S., Japan, and Europe, including recent FDA approvals for Guardant360 CDx with Pfizer's Braftovi and Arvinas and Pfizer's VEPPANU. Real-world evidence from InfinityAI contributed to the first tumor-agnostic approval of Daiichi Sankyo's ENHERTU in Japan. Strategic partnerships include a multiyear agreement with Merck and a collaboration with Nuvalent to develop companion diagnostics. The Shield Multi-Cancer Detection report, covering 9 additional cancer types, has launched in Asia through a partnership with Manulife in Hong Kong, the Philippines, and Singapore. The nationwide Quest collaboration is opening doors in health systems and physician practices where Guardant Health previously lacked a strong direct presence, and EMR connectivity has expanded to more than 650,000 HCPs. Additionally, the FDA approved reducing the Shield blood collection to 2 tubes from the original 4-tube kit to enhance patient experience.	Guardant Health believes it has been "leading the pack, frankly, in terms of real AI that has that actionable insight." The company noted that when launching new products, they tend to see "out-sized traction maybe versus, let's say, a new competitor in the market." In response to a question about consolidation and competitors like Roche with Saga and Abbott with Exact, management stated that "the bar is very high in terms of what we built organically inside the company, the growth rates, the quality of our products and so on." The company also highlighted that it is "the far and away leader in tissue-free MRD." The sales field is acknowledged as "becoming competitive."	The broader industry is experiencing a paradigm shift in oncology, with the belief that "the future of oncology and the future of therapy switching will involve ctDNA." It was noted that "it's always hard for the first paradigm shift" and that a "mountain of evidence" is required when moving from one modality to another, but once the dam is broken, it's hard to go back. The market for MRD is described as having "2 parts to it. The consumer-informed sort of MRD subset and then certainly market as well that is very, very sizable."	Guardant Health is raising its full year 2026 revenue guidance to a range of $1.30 billion to $1.32 billion, representing 32% to 34% growth. Oncology revenue is expected to grow 28% to 29% with volume growth greater than 35%, with Reveal remaining the fastest-growing oncology product. Biopharma & Data revenue is projected for low double-digit growth. Screening revenue is now expected to be $186 million to $198 million, driven by 230,000 to 245,000 Shield tests. The company anticipates a full year non-GAAP gross margin of 64% to 65% and non-GAAP operating expenses in the range of $1.05 billion to $1.07 billion. Free cash flow burn for 2026 is expected to improve to $185 million to $195 million, and the company remains committed to achieving company-wide cash flow breakeven by the end of 2027. Key upcoming initiatives include completing the Guardant360 Liquid NovaSeq X transition in May 2026, launching Reveal Ultra and FDA-approved Guardant360 Liquid, and continued expansion of the Smart platform. ACS guideline inclusion for Shield is expected in the near term. Shield's cost per test is expected to decline to approximately $200 at scale, driven by further volume growth and workflow efficiencies and automation anticipated in 2027.	Data		Our commercial flywheel has achieved a new level of velocity, delivering our fastest year-over-year percentage revenue growth in the last 5 years and surpassing the $1 billion trailing 12-month revenue milestone. We had a phenomenal start to 2026, delivering $302 million of revenue in Q1, representing 48% year-over-year growth. Reveal remained our fastest-growing product with volumes up over 100% year-over-year. Guardant360 Liquid will become the most comprehensive FDA-approved liquid biopsy for therapy selection on the market. Q1 was another strong quarter for Shield. We delivered $42 million of Shield testing revenue driven by approximately 44,000 tests compared to $6 million revenue and approximately 9,000 tests in Q1 of 2025. We are raising our full year 2026 revenue guidance to a range of $1.30 billion to $1.32 billion, representing growth of 32% to 34%. We remain committed to achieving company-wide cash flow breakeven by the end of 2027. I feel like we've been leading the pack, frankly, in terms of real AI that has that actionable insight.	These statements involve material risks and uncertainties that could cause actual results or events to materially differ from those anticipated. Our oncology guidance does not include potential upside from FDA approval of Guardant360 Liquid or the launch of Reveal Ultra. Our revenue guidance does not reflect any impact from the potential approval of camizestrant. Oncologic Drugs Advisory Committee voted [6 to 3] against the claim that camizestrant demonstrated clinically meaningful benefit. Our screening guidance does not include upside from ACS guideline inclusion. We typically don't want to get too excited and get ahead of our skis just based on 1 quarter performance. The field is becoming competitive.	Guardant Health plans to continue hiring sales representatives, noting that the quality of reps being hired continues to improve. On the oncology side, the company may split territories and add additional reps and support staff where there is no saturation and positive ROI. Incremental screening gross profit will be reinvested to support commercial expansion, including building out the sales and marketing function.

2026-02-19

About Expanding Eligible Market	About Competition	About The Broader Industry	Where Things Are Headed	Updates On Theme	Broader Themes Emerging	Bullish-Leaning Quotes (Short)	Bearish-Leaning Quotes (Short)	Hiring
Guardant Health introduced groundbreaking applications for Guardant360 Liquid, upgraded Guardant360 tissue onto their smart platform, and expanded Reveal to support therapy monitoring. The company applied Infinity AI to develop 15 smart applications on Guardant360 liquid, which are believed to meaningfully expand its clinical utility and leadership in the liquid CGP market. Global access was expanded in Q4 with the launch of Guardant360 CDx technology in Rome, Italy. Reveal received Medicare coverage for CRC surveillance in early 2025 and is generating clinical data for additional reimbursement coverage this year, with early uptake for late-stage therapy response monitoring broadening its clinical use. Data packages have been submitted to support coverage in breast cancer surveillance, immuno-oncology monitoring, and chemo monitoring, with ongoing studies across more than 5 additional tumor types. Shield expanded to include a multi-cancer detection results report and received TRICARE coverage for eligible average-risk individuals aged 45 and older. The company successfully deployed its first enterprise-scale integrations with large health systems in West Virginia and Georgia and announced collaborations with Quest Diagnostics and PathGroup to broaden national reach in 2026. There are also plans for expansion of self-pay Shield into select markets outside the U.S. In biopharma, Guardant Health is a leader in companion diagnostics with 25 approvals and a robust pipeline, including 5 new CDx approvals for Guardant360 in the last 6 months, and a multiyear agreement with Merck.	Guardant Health believes it is building a meaningful competitive moat in its oncology business through the combined strength of Guardant360 and Reveal, being uniquely positioned with scaled offerings spanning both treatment selection and monitoring. Shield's 93% adherence rate represents a meaningful improvement compared to other screening modalities, which typically range from 25% to 71%. The upcoming Reveal Ultra is expected to redefine sensitivity in the tumor-informed space. The company noted that a competitor's large multi-cancer early detection (MCED) trial did not meet its primary endpoint in terms of looking for stage shift.	There is a growing role for blood-based monitoring in cancer care. Legislation establishing a Medicare coverage pathway for multi-cancer detection tests has recently passed. The broader industry is experiencing a shift towards personalized medicine and early cancer detection, driving increased demand for advanced diagnostic solutions. CMS premium pricing (ADLT) and broad Medicare coverage for blood-based CRC and follow-on Cologuard 2, along with the Trump-era rollback of LDT rules, are accelerating payer uptake of ctDNA/MCED and AI-enabled pathology.	For full year 2026, Guardant Health expects revenue between $1.25 billion and $1.28 billion, representing 27% to 30% growth, positioning them to achieve their 2028 long-range revenue target of $2.2 billion. Oncology revenue growth is projected at 25% to 27% in 2026, with volume growth of approximately 30%, and Reveal is expected to remain the fastest-growing oncology product. Biopharma and data revenue is forecasted for low double-digit growth in 2026. Screening revenue is expected to be in the range of $162 million to $174 million from 210,000 to 225,000 tests in 2026. The core business (excluding screening) is expected to be free cash flow positive for the full year 2026, with the company committed to achieving company-wide cash flow breakeven by the end of 2027. Free cash flow burn for 2026 is anticipated to improve to $185 million to $195 million. Upcoming oncology product launches include Guardant360 Liquid CDx, an ESR1 monitoring test, and Reveal Ultra. In screening, the company anticipates inclusion in ACS guidelines, commercial expansion with Quest, and international self-pay Shield expansion. The transition of Guardant360 liquid tests to NovaSeq X is expected to be fully implemented around the middle of 2026.	**HC		2025 was a breakout year for Guardant, where years of investment continues to fuel breakthrough innovation and best-in-class execution across our portfolio. This exceptional performance reflects continued broad-based growth across our oncology screening and biopharma and data businesses. Shield is the most successful diagnostic launch in history outside of COVID testing and is positioned to be a significant multiyear growth driver for Guardant. We expect the core business to be free cash flow positive for the full year 2026 and remain committed to achieving company-wide cash flow breakeven by the end of 2027. We're feeling really good about how we're sort of managing the burn.	These statements involve material risks and uncertainties that could cause actual results or events to materially differ from those anticipated. This is just the second year of launch, and we want to be thoughtful with our guidance. We typically don't want to get too excited and get ahead of our skis just based on 1 quarter performance. Q1 seasonality in PCP offices is kind of normal. Our screening guidance does not include potential upside from Quest co-promotion activities as well as ACS guideline inclusion.	Guardant Health significantly expanded its commercial team and established strategic partnerships to meet growing demand for blood-based screening. The commercial organization for Shield scaled throughout 2025, exiting the year with approximately 300 sales reps, and will continue to build out in 2026, with incremental gross profit invested in sales and marketing, primarily for building the sales force and hiring more people. The acquisition of MetaSight Diagnostics also brought on an impressive team, strengthening the world-class R&D organization.

NotesTable

Date	Comment	Comment Type	Comment Sentiment	Link	Price Reaction
2026-02-19	Guardant Health reported strong Q4/FY25 revenue and volume growth, with Shield exceeding expectations and the core business achieving positive free cash flow. The company issued bullish 2026 guidance, projecting continued expansion and a path to profitability. However, the stock significantly underperformed the market post-earnings, suggesting investor skepticism regarding the pace of profitability or the aggressive investment in screening despite positive operational updates.	Other	Neutral		-3.08% (vs SPY: -2.77%)

Upcoming Events4 rows

Catalyst ID	Estimated Timing	Estimated Date Start	Estimated Date End	Catalyst	Why It Matters	Ticker Or Theme Specific	Transcript Date	Source Type
GH_551c816d	in 2026	2026-01-01	2026-12-31	Launch of Guardant Reveal Ultra, the tumor-informed MRD/therapy monitoring test, expected to ship this year.	Could drive higher oncology volumes and strengthen Guardant360/Reveal synergy, improving growth prospects and competitive moat.	Ticker	2026-02-19	earnings_transcript
GH_a329742a	pending FDA approval; timing to be determined (2026 or later)	2026-01-01	2027-12-31	Guardant360 Liquid CDx launch following FDA approval.	Adds a concurrent CDx option, potentially expanding addressable market and cross-sell; regulatory milestone risk.	Ticker	2026-02-19	earnings_transcript
GH_4e822abd	2026–2027 timeframe	2026-07-01	2027-12-31	AstraZeneca SERENA-6 trial results; potential to drive ESR1 monitoring adoption and Guardant360 volumes if positive.	Positive SERENA-6 results could accelerate therapy-monitoring use and overall Guardant360 demand; risk to sentiment if results are negative.	Ticker	2026-02-19	earnings_transcript
GH_17aaaacc	near term (2026)	2026-01-01	2026-12-31	ACS guideline inclusion for Shield; near-term potential to expand payer coverage and physician adoption.	Could drive Shield volumes and broaden market access, supporting volume growth.	Ticker	2026-02-19	earnings_transcript